Health-related quality-of-life analyses from a multicenter, randomized, double-blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day

By sjmartinez • March 3, 2023

Taylor MH, Leboulleux S, Panaseykin Y, Konda B, de La Fouchardiere C, Hughes BGM, Gianoukakis AG, Park YJ, Romanov I, Krzyzanowska MK, Garbinsky D, Sherif B, Pan JJ, Binder TA, Sauter N, Xie R, Brose MS. Health-related quality-of-life analyses from a multicenter, randomized, double-blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day. Cancer Med. 2023 Feb;12(4):4332-4342. doi: 10.1002/cam4.5308. Epub 2022 Dec 4. PMID: 36464853; PMCID: PMC9972135.

Tags: dose intensity, Endocrinology, Harbor UCLA, HRQoL, kinase inhibitor, lenvatinib, Quality of Life, radioiodine-refractory differentiated thyroid cancer

Continuous Glucose Monitoring in Type 2 Diabetes: Clinical Outcomes, Disparities in Access, and Cost-effectiveness

Perini Villanueva G, Solorzano WM, Everett E. Continuous Glucose Monitoring in Type 2 Diabetes: Clinical Outcomes, Disparities in Access, and Cost-effectiveness. Curr Diab Rep. 2026[...]

Spatial transcriptome mapping identifies Ppara-Anxa2 cross-talk in microplastic-induced hepatotoxicity

Jung W, Abushukair H, Patil NY, Ampadu F, Firouzi M, Rus I, Choi J, Muthukrishnan SD, Shukla S, Tarantini S, Csiszar A, Mehla K, Kim[...]

Targeting lysosomal pH restores mitochondrial quality control in GBA1-mutant Parkinson’s disease

Sheshadri P, Costa-Besada MA, Fisher A, Kiraly S, Singh K, Kourouzidou I, Blacker TS, Zeng J, Shirihai OS, Grinstaff MW, Duchen MR. Targeting lysosomal pH[...]